Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 20

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 20
---
 2023 Placement Agent Warrants after receiving required shareholder approval of
the allotment of, and disapplication of pre-emption rights with respect to the Ordinary Shares to be issued under the warrants at our
June GM.

Between June 20, 2023,
and June 30, 2025, we have issued 166,017,700 Ordinary Shares upon the exercise of Series C Warrants issued in the May 2023 registered
direct offering.

On July 5, 2023, we effected
a ratio change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such that one
Depositary Share represented 400 Ordinary Shares. Our Ordinary Shares were not affected by this change and no fractional Depositary Shares
were issued.

On November 22, 2023,
we entered into a series of agreements with (1) Adhera Therapeutics, Inc. and certain of its secured noteholders, or the Secured
Noteholders, and (1) Melior Pharmaceuticals I, Inc, or Melior. On December 21, 2023, in connection with the closing under the agreements,
we issued (A) an aggregate of (i) 899 Depositary Shares to certain of the Secured Noteholders and (ii) 9,098 December 2023 Private Placement
Pre-Funded Warrants to certain of the Secured Noteholders, and (B) 1,417 Depositary Shares to Melior. Between December 21, 2023 and June
30, 2025, we have issued 738,002,400 Ordinary Shares upon the exercise of December 2023 Private Placement Pre-Funded Warrants issued
to the Secured Noteholders.

On December 21, 2023,
we completed the closing of an underwritten public offering, pursuant to which we issued and sold (i) 4,355 Class A units, or Class A
Units, at a public offering price of $500.00 per Class A Unit, with each Class A Unit consisting of (a) one Depositary Share, (b) one
Series E Warrant, and (c) one Series F Warrant, and (ii) 7,644 Class B units, or Class B Units, at a public offering price of $269.999
per Class B Unit, with each Class B Unit consisting of (a) one pre-funded warrant, exercisable for one Depositary Share, (b)